Real-Life Renal Safety of Boosted TDF in HIV/HCV Patients on SOF/LDV
Ledipasvir increases tenofovir (TDF) exposures. In individuals taking EVG/COBI/TDF/FTC or TDF with a ritonavir (RTV)-boosted HIV PI, higher TDF exposures may increase the risk of renal toxicity. To evaluate the renal safety of 12 or 24 weeks of Sofosbuvir/Ledispasvir (SOF/LDV), according to boosted TDF exposure, in a cohort of 159 HIV/HCV co-infected patients at a…